<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098003</url>
  </required_header>
  <id_info>
    <org_study_id>832874</org_study_id>
    <nct_id>NCT04098003</nct_id>
  </id_info>
  <brief_title>Investigation of the Gut Microbiome and Statin Response</brief_title>
  <acronym>INGEST</acronym>
  <official_title>INvestigation of the Gut microbiomE and STatin Response (INGEST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sony Tuteja</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence that the bacteria that naturally reside in the gut can influence how well&#xD;
      we respond to medications. Therefore this study will look at how rosuvastatin, a medication&#xD;
      used to lower cholesterol levels, may change the bacteria in the gut. Investigators will also&#xD;
      examine how the gut bacteria will affect the ability of rosuvastatin to lower cholesterol&#xD;
      levels. There will be 4 study visits over the course of about 16 weeks.The expected duration&#xD;
      of the study is 2 years. Investigators plan to enroll 100 healthy volunteers during that&#xD;
      time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The gut microbiome plays an important role in the metabolism of xenobiotics and contributes&#xD;
      to the variation in drug response. Atorvastatin, simvastatin and rosuvastatin, three of the&#xD;
      most commonly prescribed statin medications, also display evidence for modulation by the gut&#xD;
      microbiome.The objective of this study is to understand the interaction between the gut&#xD;
      microbiome and host drug response to statin therapy using 16S rRNA sequencing, metagenomics&#xD;
      sequencing and bile acid metabolomics.&#xD;
&#xD;
      Aim 1: To compare changes in the gut microbiome in healthy volunteers randomized to an 8-week&#xD;
      intervention with rosuvastatin 10mg daily or placebo.&#xD;
&#xD;
      Aim 2: To determine the relationship with gut microbiome, fecal bile acid composition, serum&#xD;
      FGF19 levels and the change in plasma LDL-C with rosuvastatin.&#xD;
&#xD;
      This is a randomized, placebo controlled trial to investigate the effects of rosuvastatin on&#xD;
      the gut microbiome, fecal bile acids and FGF19 levels. Healthy volunteers will be randomized&#xD;
      to rosuvastatin 20 mg daily or placebo for eight weeks in a 2:1 ratio. Participants will be&#xD;
      blinded to treatment assignment. Stool and blood will be collected at baseline, 8 weeks, and&#xD;
      12 weeks for 16S sequencing, plasma lipid assays, bile acid metabolites and FGF19 assays. A&#xD;
      subgroup of participants at the tails of LDL-C response will undergo metagenomics sequencing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2020</start_date>
  <completion_date type="Anticipated">April 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized, placebo controlled, double blind (participant and outcomes assessor) trial to investigate the effects of rosuvastatin on the gut microbiome. Healthy volunteers will be randomized to rosuvastatin 20 mg daily or placebo for eight weeks in a 2:1 ratio.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Matching placebo capsules will be formulated</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bacterial abundance</measure>
    <time_frame>8 weeks</time_frame>
    <description>as measured by operational taxonomic units (OTUs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-C</measure>
    <time_frame>8 weeks</time_frame>
    <description>low density lipoprotein cholesterol levels (mg/dl)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in fecal bile acid concentrations</measure>
    <time_frame>8 weeks</time_frame>
    <description>concentration of bile acids (nM)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum FGF19 levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>Fibroblast growth factor 19 levels (pg/mL)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rosuvastatin 20 mg daily for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo daily for eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>rosuvastatin 20 mg daily or placebo for eight weeks</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is capable of giving informed consent&#xD;
&#xD;
          2. Participant is aged 18 to 65 years. The gut microbiome has been shown to change&#xD;
             gradually with time, although there is no cut-off in age when this occurs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with cardiovascular disease such as a history of heart failure (New York&#xD;
             Heart Association class II-IV), myocardial infarction, stroke, coronary artery bypass&#xD;
             graft, hypertension, and hyperlipidemia as these conditions are associated with&#xD;
             altered gut microbiome composition.74 Hypertension is defined as blood pressure&#xD;
             greater than 160/110 or on any anti-hypertensive medications. LDL-C &gt;190 mg/dl or &lt;100&#xD;
             mg/dl and triglycerides &gt; 400 mg/dl.&#xD;
&#xD;
          2. Participants with a history of cancer.&#xD;
&#xD;
          3. Kidney disease (serum creatinine &gt;1.5 mg/dl).&#xD;
&#xD;
          4. Liver dysfunction (alanine aminotransferase &gt; 2 times the upper limit of normal).&#xD;
&#xD;
          5. Diabetes mellitus (DM) - Diabetes itself may affect the gut microbiome although this&#xD;
             has not been extensively studied. In addition to a prior diagnosis of diabetes&#xD;
             mellitus other than that related to pregnancy, a fasting glucose level of greater than&#xD;
             125mg/dL will be used to exclude participation.&#xD;
&#xD;
          6. Clinical diagnosis of hypothyroidism&#xD;
&#xD;
          7. History of inflammatory disorders of the intestinal tract (i.e. IBD, celiac sprue).&#xD;
&#xD;
          8. Use of antibiotics in the prior 6 months.&#xD;
&#xD;
          9. Use of pre-, pro-, or synbiotics.&#xD;
&#xD;
         10. Chronic medication use (including over the counter medications and herbal supplements)&#xD;
             with the exception of oral contraceptives. Since we are evaluating the impact of&#xD;
             rosuvastatin on the gut microbiome we would like to exclude the potential impact of&#xD;
             confounding medications.&#xD;
&#xD;
         11. Current smoker. The effect of smoking on the microbiome of the gut is unknown.&#xD;
&#xD;
         12. Known history of alcohol or substance abuse.&#xD;
&#xD;
         13. Body Mass Index (BMI) &lt;18.5 or &gt;30 kg/m2. Volunteers with BMI below normal will be&#xD;
             excluded to prevent inclusion of subjects with a subclinical systemic disease that may&#xD;
             influence the gut microbiome. Volunteers with moderate or severe obesity will be&#xD;
             excluded as obesity may be associated with altered gut microbiome composition.31&#xD;
&#xD;
         14. Unable to abstain from consumption of illicit drugs during the study period.&#xD;
&#xD;
         15. Prior bowel resection surgery other than appendectomy. It is unknown how prior bowel&#xD;
             resection surgery may influence the microbiome composition; hence we will exclude&#xD;
             these participants.&#xD;
&#xD;
         16. Baseline bowel frequency less than every 2 days or greater than 3 times daily. Normal&#xD;
             bowel frequency is every 3rd day to 3 times per day. Although unknown, stool frequency&#xD;
             could be related to the microbiome composition. To avoid the need for use of&#xD;
             antidiarrheal medications or laxatives, which themselves could alter the microbiome&#xD;
             composition, these patients will be excluded.&#xD;
&#xD;
         17. Participant has experienced diarrhea within the two weeks prior to entry. Diarrhea is&#xD;
             defined as a change in bowel habits with an increased frequency or loose stools such&#xD;
             that the stool could not be lifted with a fork.&#xD;
&#xD;
         18. Vegans and Vegetarians.&#xD;
&#xD;
         19. Known intolerance to statin medications.&#xD;
&#xD;
         20. Unwilling to obtain from grapefruit containing foods or drinks.&#xD;
&#xD;
         21. Pregnant women. To avoid any risk to an unborn fetus from study drug exposure.&#xD;
&#xD;
         22. Refusal to use two medically accepted method of birth control while participating in&#xD;
             the study, such as a barrier method, hormonal contraceptives, implanted birth control&#xD;
             devices, permanent methods (such as a vasectomy), and/or abstinence.&#xD;
&#xD;
         23. Nursing mothers&#xD;
&#xD;
         24. Any condition that the investigator feels may limit the volunteer's ability to&#xD;
             complete the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sony Tuteja, PharmD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Perelman School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sony Tuteja, PharmD, MS</last_name>
    <phone>215-573-7834</phone>
    <email>sonyt@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Terembula, BS</last_name>
    <phone>215-615-3423</phone>
    <email>kterembu@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Terembula, BS</last_name>
      <phone>215-615-3423</phone>
      <email>kterembu@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Sony Tuteja</investigator_full_name>
    <investigator_title>Research Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>gut microbiome</keyword>
  <keyword>statins</keyword>
  <keyword>cholesterol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

